Sun spots and PIH: the difference matters because the treatment is not the same

The biological difference between UV-induced sunspots and post-inflammatory hyperpigmentation

Solar lentigines (sunspots, age spots, liver spots) are regions of melanocyte hyperactivity where cumulative UV exposure over years has permanently upregulated tyrosinase activity in a localised cluster of melanocytes — these cells produce more melanin than surrounding melanocytes regardless of current UV exposure level. Post-inflammatory hyperpigmentation (PIH) results from a different mechanism: the inflammatory response to acne, eczema, psoriasis, a burn, a rash or any other inflammatory event triggers melanocyte activation through prostaglandins, leukotrienes and other inflammatory mediators that stimulate tyrosinase as a bystander effect of the inflammation. PIH is more responsive to treatment than solar lentigines because it is driven by an active inflammatory signal that eventually resolves, rather than by a permanent upregulation of tyrosinase in specific melanocytes. In darker skin tones, PIH is more common and more persistent than in lighter tones because the higher baseline melanocyte activity in darker skin produces a more significant inflammatory hyperpigmentation response.

Why antioxidants and SPF are the primary treatment for solar lentigines

Solar lentigines represent permanently hyperactive melanocytes — reducing their output requires either permanently inhibiting their tyrosinase activity (which no current topical cosmetic achieves durably), preventing further UV stimulation (which SPF addresses), or supporting the natural cell renewal cycle that eventually surfaces and sheds the pigment-containing keratinocytes (which AHA exfoliation and consistent turnover support). For solar lentigines, the most effective topical approach combines SPF (preventing ongoing UV activation of already-hyperactive melanocytes), vitamin C serum (tyrosinase inhibition and antioxidant protection against UV-triggered melanogenesis), and AHA exfoliation (accelerating the shedding of melanin-containing surface cells). The response is slow — twelve to twenty-four weeks of consistent application — because the result comes from cell shedding rather than from a change in melanocyte behaviour.

PIH treatment: targeting the inflammatory trigger first

For post-inflammatory hyperpigmentation, the most important step is addressing the inflammatory trigger that is activating melanocyte tyrosinase. Ongoing acne inflammation continues to produce PIH regardless of how many brightening actives are applied — the melanocyte is still receiving inflammatory prostaglandin signals from the active breakout, which override the tyrosinase inhibition of topical niacinamide or vitamin C. Resolving the active inflammation (through appropriate acne treatment) before or alongside brightening treatment produces significantly better outcomes than brightening treatment applied to skin that is still inflamed. Once the inflammatory trigger is resolved, the melanin in PIH is in a melanocyte that has returned to baseline activity — the excess melanin can be shed through AHA exfoliation and the transfer of existing melanin inhibited by niacinamide, producing visible lightening over eight to twelve weeks.

The melanon brightening cream approach: multiple mechanisms for surface pigmentation

A melanon brightening cream that targets melanin synthesis, transfer and retention through multiple mechanisms provides the comprehensive surface-level brightening that addresses both solar lentigines and resolved PIH simultaneously. A formula that combines melanin-synthesis inhibition (kojic acid, arbutin, tranexamic acid or multi-plant melanon complexes) with barrier-supporting emollients delivers the brightening actives in a format with extended surface contact time — the cream vehicle's slower evaporation produces more contact time between the brightening actives and the surface melanin-containing cells than a water-based brightening serum. For the final step of the evening brightening routine, a cream format over the brightening toner provides this extended surface contact for the night-time surface renewal period.

Building the brightening routine that works for both spot types simultaneously

A brightening routine that addresses both UV-induced spots and PIH in the same sequence: morning — rice toner (antioxidant protection from ferulic acid, reducing UV-triggered melanogenesis before it starts), niacinamide serum (melanin transfer inhibition daily), SPF50+ broad spectrum (preventing ongoing UV activation of existing solar lentigines). Evening — gentle cleanser, AHA toner once or twice weekly (surface melanin-cell shedding acceleration), melanon brightening cream (extended surface contact with melanin-synthesis inhibiting actives). The morning antioxidant step reduces new PIH formation from UV exposure; the niacinamide addresses daily melanin transfer inhibition; the evening AHA progressively surfaces and sheds existing pigment cells; and the melanon cream provides targeted brightening active contact with the pigmented surface. Consistent application of this four-product sequence for twelve weeks produces measurable improvement in both spot types.